This article is more than 5 years old. Information may no longer be current.

玻璃体切割术前使用抗VEGF降低出血风险

Issue: December 2008

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

一项研究显示，玻璃体切割术前，给患者注射贝伐单抗可降低出血的风险。

“这项随机、安慰剂对照的临床试验显示，玻璃体内使用贝伐单抗可有效降低糖尿病患者玻璃体切开后术后早期的玻璃体出血率，”医学博士拉明·蒙什扎德(Ramin Monshizadeh)说：“非透明性玻璃体出血眼，注射贝伐单抗还可明显减少对玻璃体切开术的需要。”

这项前瞻性的双盲研究，调查了68名因糖尿病增殖性视网膜病变，而做睫状环玻璃体切割术和光凝术患者的68只眼。各患者术前都接受一周的假注射或1.25 mg贝伐单抗。

治疗组9名患者的出血缓解，避免了玻璃体切割术。对照组的两只眼同样缓解。

“手术后一周，贝伐单抗组玻璃体出血的严重程度明显低于对照组，”蒙什扎德博士说：“第1个月术后玻璃体出血，贝伐单抗组与对照组相比明显降低。”

他说，最佳矫正视力也改善，治疗组的变化为–1.05 logMAR，对照组的变化为–0.42 logMAR。